Navigation Links
EULAR in Medical News

Trubion Pharmaceuticals, Inc. to Present Positive Data From a Phase 2b Re-treatment Study of TRU-015 at the 2009 EULAR Annual Meeting

SEATTLE, May 18 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN ) announced today that data from the re-treatment portion of a Phase 2b study (15002) of TRU-015 for rheumatoid arthritis will be presented on June 11 at the 2009 European League Against Rheumatism (EULAR) annu...

Press registration is now open for EULAR 2009, June 10-13, Copenhagen

Journalist registrations are now being accepted for EULAR, the European League Against Rheumatism's 10th annual meeting, taking place 10th-13th June 2009 in Copenhagen, Denmark. Press registration is free of charge for all holders of a valid press card / formal journalist credentials. Press w...

Better access to info and dialogue with HCPs on sexual issues for rheumatology patients

...mmunication with healthcare professionals on the sexual issues related to their conditions, according to the results of a new study presented today at eular 2009, the Annual Congress of the European League Against Rheumatism in Copenhagen, Denmark. However, a second study shows that, although nurses und...

RA individuals from lower GDP countries keep working despite worse symptoms than richer countries

...onal disability scores compared to their counterparts in higher GDP countries (GDP >$24,000) according to a new multinational study presented today at eular 2009, the Annual Congress of the European League Against Rheumatism in Copenhagen, Denmark. Among 1,650 individuals from 30 countries whose symptom...

Over half of people with rheumatoid arthritis have periodontitis

...nalysis computer programme) p Moderate to Severe Periodontitis may be a Risk Factor for Developing RA in Non-Smokers A second study presented at eular 2009 showed that, although smoking is an established risk factor for both RA and periodontitis, non-smoking individuals with moderate to severe period...

IFX anti-TNF therapy associated with clinical benefit over 5 years in patients with active AS

...tate and low creactive protein (CRP, a marker for inflammation) levels, according to the results of a new openlabel follow-up study presented today at eular 2009, the Annual Congress of the European League Against Rheumatism in Copenhagen, Denmark. AS is the most frequent chronic inflammatory rheumatic ...

63 percent of RA patients suffer psychiatric disorders, with depressive spectrum conditions most likely

...ychiatric disorders, with the majority of these (87%) occurring in the depressive spectrum, according to the results of a new study presented today at eular 2009, the Annual Congress of the European League Against Rheumatism in Copenhagen, Denmark. Interestingly, over half (52%) of the patients studied ind...

Anxiety and depression lower quality of life in majority of systemic lupus erythematosus patients

...ession which significantly affects both their physical and emotional quality of life (QoL), according to the results of a new study presented today at eular 2009, the Annual Congress of the European League Against Rheumatism in Copenhagen, Denmark. Logistic regression analysis revealed that depression was ...

Diagnosis of arthritis 5 years earlier in childless women compared to those with children

...atoid arthritis (RA) an average of 5.2 years before parous women (those who have given birth to children), according to a new study presented today at eular 2009, the Annual Congress of the European League Against Rheumatism in Copenhagen, Denmark. Previous studies have highlighted that pregnancy may be ...

Novel DNA vaccine leads to kidney damage prevention in systemic lupus erythematosus models

...cific tolerance and may help to prevent kidney damage in patients with systemic lupus erythematosus (SLE), according to a new study presented today at eular 2009, the Annual Congress of the European League Against Rheumatism in Copenhagen, Denmark. SLE is a complex, chronic autoimmune disease that causes...
EULAR in Medical Technology

NicOx Announces Blood Pressure Analysis From 301 Phase 3 Study for Naproxcinod at EULAR

SOPHIA ANTIPOLIS, France, June 13 /PRNewswire-FirstCall/ -- NicOx S.A. (Euronext Paris: COX) today announced an additional analysis of the blood pressure data from the 301 phase 3 study, showing a statistically significant difference between naproxcinod and naproxen in terms of the mean chan...

Novel Mechanism Insights and Additional Data on CombinatoRx Drug Candidates to Be Presented at Upcoming EULAR Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun 6, 2007 - CombinatoRx, Incorporated (NASDAQ: CRXX), today announced that data from its randomized, blinded, placebo-controlled phase 2 clinical trials of CRx-102 in patients with osteoarthritis (OA) and rheumatoid arthritis (RA) will be featured at the Europea...

New Data on Genmab and GlaxoSmithKline's Ofatumumab: Phase II Study in Rheumatoid Arthritis to be Presented at EULAR

COPENHAGEN, Denmark; April 25, 2007 - Genmab A/S (CSE: GEN) announced today that the results of a Phase II study with ofatumumab (HuMax-CD20™) in patients with rheumatoid arthritis (RA) have been accepted for oral presentation at the 2007 Annual European Congress of Rheumatology (EULAR). The...

Enbrel Safety Data for up to Eight Years in Patients with Juvenile Rheumatoid Arthritis Being Presented at EULAR

THOUSAND OAKS, Calif. & COLLEGEVILLE, Pa.--(BUSINESS WIRE)--Jun 13, 2007 - Amgen (NASDAQ:AMGN) and Wyeth Pharmaceuticals, a division of Wyeth (NYSE:WYE), today announced the presentation of additional data that showed that the safety profile of Enbrel(R) (etanercept) was maintained with long-te...

Additional Data on CombinatoRx Drug Candidates CRx-102 and CRx-139 Presented at EULAR

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun 14, 2007 - CombinatoRx, Incorporated (NASDAQ: CRXX) today announced the presentation of additional data related to its immuno-inflammatory product candidates, CRx-102 and CRx-139, at the European League Against Rheumatism (EULAR) Annual Congress of Rheumatolog...

Two-Year Data Show Patients Receiving SIMPONI(TM) (golimumab) Experienced Sustained Improvement in Signs and Symptoms of Psoriatic Arthritis and Ankylosing Spondylitis

... Long-Term Data in Patients Receiving Every-Four-Week Subcutaneous SIMPONI Presented at 2009 eular Annual Congress COPENHAGEN, June 9 /PRNewswire/ -- Findings from open-labeled, uncontrolled extensions of two randomized, placebo-controlled Ph...

ACTEMRA (R) (tocilizumab) Significantly Reduced Signs and Symptoms of Rheumatoid Arthritis in Patients Who Failed Prior Treatments

... to 3.2), moderate (3.2 5.1). DAS28<2.6 corresponds to being in remission according to the criteria of the American College of Rheumatology. (3) The eular response criteria is based on the individual amount of change in DAS and the DAS value (low, moderate, high disease activity) reached to classify pati...

ACTEMRA(R) (tocilizumab) Significantly Reduces Rheumatoid Arthritis Signs and Symptoms Regardless of Previous Therapy in Two New Global Studies

...low (DAS28 less than or equal to 3.2), moderate (3.2 (DAS28>5.1). DAS28 the criteria of the American College of Rheumatology. (3) The eular response criteria is based on the individual amount of change in DAS and the DAS value (low, moderate, high disease activity) reached to cla...

Human Genome Sciences Reports Positive Long-Term Data for LymphoStat-B in Patients With Active Systemic Lupus Erythematosus

...16/HGSLOGO ) "Based on the results presented at eular 2008, the clinical benefit observed for belimumab ... Through Three Years The data presented today at eular 2008 demonstrate that continued treatment with bel...Kline clinical development pipeline. To view the eular oral presentation reporting results of the Phase 2...

Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594

...594's activity in the target population using its prodrug, RDEA806. This study is on track to be initiated in the second quarter of this year. The eular presentation details are as follows: Date/Time: Thursday, June 12, 2008 from 11:45 a.m. - 1:30 p.m. CEST Title: Safety and Uric Acid Lowering Eff...
EULAR in Medical Dictionary

Rheumatism

...umatism in the free online English dictionary and ... rheumatism ... rheumatism - a chronic autoimmune disease with inflammation of ... eular - The European League Against Rheumatism . BBC "Your Health" website on Arthritis and Rheumatism . e-medicine article on Non-Articular Rheumatism ...
EULAR in Biological Technology

Human Genome Sciences Reports Positive Long-Term Data for BENLYSTA(TM) (Formerly LymphoStat-B(R)) in Patients With Active Systemic Lupus Erythematosus

...SLOGO ) "Based on the results presented at eular 2009, the apparent durability of clinical effect a...rough Four Years The data presented today at eular 2009 showed that continued treatment with belimuma...activity). The data presented at eular 2009 suggest that belimumab was generally well tol...

European CHMP Adopts Negative Opinion on Cymbalta for the Treatment of Fibromyalgia

... 1999; 40(1):59 (10) Rao, SG, et al. Understanding the Fibromyalgia Syndrome. Psychopharmacology Bulletin. 2007: 4:24-67 (11) Carville, SF, et al. eular Evidence-based Recommendations for the Management of Fibromyalgia Syndrome. Ann Rheum Dis. Republished 2008: 67: 536-541. P-LLY (Logo: http://www...
Other Tags
(Date:7/9/2014)... the most common type of lung cancer, researchers have ... role in forming tumors. The new knowledge may expand ... genetic changes already are available or are in clinical ... investigators from The Cancer Genome Atlas (TCGA), including researchers ... Harvard Medical School and other institutions, studied tumors from ...
(Date:7/9/2014)... from The Miriam Hospital have found that people ... also depressed have difficulty sticking to a pulmonary ... for women, and screening and brief treatment of ... The study and its findings are published in ... Chronic obstructive pulmonary disease is a common and ...
(Date:7/9/2014)... declines and extinctions around the world have been ... but new research from the National Institute for ... pathogen, ranavirus, may also contribute. , In ... ranavirus, which causes severe hemorrhage of internal organs ... of wood frogs if they are exposed to ...
(Date:7/9/2014)... study conducted by researchers at Tufts University School of ... intellectual and developmental disabilities, the likelihood of having cavities ... increased. The findings, published in the July/August issue of ... interventions designed to address the oral health of individuals ... dental records of 107 patients at one of the ...
(Date:7/9/2014)... allergic diseases has risen dramatically in Western societies. One ... to microorganisms and have fewer infections than previous generations, ... study by researchers at Sahlgrenska Academy, University of Gothenburg, ... maturation of the immune system in relation to allergic ... of the Vstra Gtaland Region, half of them on ...
Breaking Medicine News(10 mins):Health News:Lung cancer study hints at new treatments 2Health News:Miriam Hospital study examines effect of depressed mood on pulmonary rehab completion 2Health News:Study predicts ranavirus as potential new culprit in amphibian extinctions 2Health News:Adults with special needs see gains, challenges with long term oral care 2Health News:Adults with special needs see gains, challenges with long term oral care 3
(Date:7/9/2014)... co-authored by a University of Guelph scientist that ... shows long-term exposure to a neonicotinoid pesticide hampers ... research by Nigel Raine, a professor in Guelph,s ... Imperial College London was published July 9 in ... . , The study shows how long-term pesticide ...
(Date:7/9/2014)... fever but often can be defeated with antibiotics and ... beat. Now, scientists have built a new weapon against such ... the journal ACS Applied Materials & Interfaces , their ... of them than medicine alone. , David Leong, Jianping Xie ... wait, undetectable in the human body or in places that ...
(Date:7/9/2014)... developed by researchers at the NIH,s National ... its collaborators to treat sickle cell disease ... business. The drug candidate, Aes-103, is the ... molecular mechanism of sickle cell disease. Baxter ... required for regulatory approval and commercialization. , ...
Breaking Biology News(10 mins):Bee foraging chronically impaired by pesticide exposure: Study 2First drug candidate from NIH program acquired by biopharmaceutical company 2First drug candidate from NIH program acquired by biopharmaceutical company 3First drug candidate from NIH program acquired by biopharmaceutical company 4
Other Contents